Suppr超能文献

低恶性潜能原发性非浸润性乳头状尿路上皮肿瘤及膀胱低级别尿路上皮癌及其相关正常尿路上皮中9q32 - 33(DBC1基因座)的杂合性缺失。

Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.

作者信息

Lopez-Beltran A, Alvarez-Kindelan J, Luque R J, Blanca A, Quintero A, Montironi R, Cheng L, Gonzalez-Campora R, Requena M J

机构信息

Department of Pathology, Reina Sofia University Hospital and Cordoba University Medical School, Spain.

出版信息

J Pathol. 2008 Jul;215(3):263-72. doi: 10.1002/path.2353.

Abstract

Tumour recurrence has a major impact on patients with non-invasive papillary urothelial tumours of the bladder. To explore the role of DBC1 (deleted in bladder cancer 1 locus), a candidate tumour suppressor gene located at 9q32-33, as prognostic marker we have performed loss of heterozygosity (LOH) testing in 49 patients with primary papillary urothelial tumours and associated normal urothelium. Data from the 38 tumours and 11 specimens of normal urothelium that were informative in the LOH study (D9S195 marker) showed that LOH in urothelium (45.4%) but not in non-invasive tumours (60.5%) was associated with tumour recurrence (p = 0.026) but not to grade or progression. Also, tumours whose normal urothelium had LOH were larger (p = 0.020) and showed cyclin D1 over-expression (p = 0.032). Non-significant increased expression of p53, p21Waf1, apoptotic index and tumour proliferation, and decreased expression of p27Kip1 or cyclin D3 also characterized tumours whose normal urothelium had LOH. The expression of these G1-S modulators, apoptotic index and tumour proliferation was more heterogeneous in papillary urothelial tumours, irrespective of having retained heterozygosity or LOH. Also, Bax expression decreased in papillary urothelial tumours having LOH (p = 0.0473), but Bcl-2 was unrelated to LOH status. In addition, FGFR3 protein expression decreased in LOH tumours (p = 0.036) and in those having LOH in their normal urothelium (p = 0.022). FGFR3 immunohistochemical expression was validated by western blot in selected cases. The survival analysis selected LOH in normal urothelium as a marker of disease-free survival (log-rank 5.32, p = 0.021), progression-free survival (log-rank 3.97, p = 0.046) and overall survival (log-rank 4.26, p = 0.038); LOH in tumours was significant in progression-free survival (log-rank 3.83, p = 0.042). It is concluded that LOH at the DBC1 locus in normal urothelium seems to be relevant in the prognosis of non-invasive papillary tumours of the bladder via selecting cases with increased proliferation, frequent alterations of the G1-S phase modulators, and decreased FGFR3 protein expression.

摘要

肿瘤复发对膀胱非浸润性乳头状尿路上皮肿瘤患者有重大影响。为了探究位于9q32 - 33的候选抑癌基因DBC1(膀胱癌1位点缺失基因)作为预后标志物的作用,我们对49例原发性乳头状尿路上皮肿瘤患者及其相关正常尿路上皮进行了杂合性缺失(LOH)检测。来自LOH研究(D9S195标记)中有信息的38个肿瘤和11个正常尿路上皮标本的数据显示,尿路上皮中的LOH(45.4%)而非非浸润性肿瘤中的LOH(60.5%)与肿瘤复发相关(p = 0.026),但与分级或进展无关。此外,正常尿路上皮有LOH的肿瘤更大(p = 0.020)且显示细胞周期蛋白D1过表达(p = 0.032)。正常尿路上皮有LOH的肿瘤还具有p53、p21Waf1表达非显著增加、凋亡指数和肿瘤增殖增加以及p27Kip1或细胞周期蛋白D3表达降低的特征。这些G1 - S调节因子的表达、凋亡指数和肿瘤增殖在乳头状尿路上皮肿瘤中更具异质性,无论是否保留杂合性或存在LOH。此外,有LOH的乳头状尿路上皮肿瘤中Bax表达降低(p = 0.0473),但Bcl - 2与LOH状态无关。另外,LOH肿瘤中FGFR3蛋白表达降低(p = 0.036),正常尿路上皮有LOH的肿瘤中FGFR3蛋白表达也降低(p = 0.022)。在选定病例中通过蛋白质印迹法验证了FGFR3免疫组化表达。生存分析将正常尿路上皮中的LOH选为无病生存期(对数秩检验5.32,p = 0.021)、无进展生存期(对数秩检验3.97,p = 0.046)和总生存期(对数秩检验4.26,p = 0.038)的标志物;肿瘤中的LOH在无进展生存期方面具有显著性(对数秩检验3.83,p = 0.042)。结论是,正常尿路上皮中DBC1位点的LOH似乎通过选择增殖增加、G1 - S期调节因子频繁改变以及FGFR3蛋白表达降低的病例,与膀胱非浸润性乳头状肿瘤的预后相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验